Not Yet Recruiting PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT06391645

Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis (NATURAL)

Sponsor: Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation

Conditions Amyotrophic Lateral Sclerosis

Updated 3 times since 2024 Last updated: Apr 25, 2024 Started: May 31, 2024 Primary completion: Dec 31, 2025 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Amyotrophic Lateral Sclerosis, this trial is actively recruiting participants. The trial is conducted by Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation and has accumulated 3 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Not Yet Recruiting PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
May 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Healthunion Cardio-Cerebrovascular Disease Prevention and Treatment Foundation
Beijing Tiantan Hospital
Beijing University of Chemical Technology

Data source: Beijing Tiantan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.